About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker OGN · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 10, 2026A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to…
NCT07265479 · Atopic Dermatitis
Tapinarof cream, 1%, Vehicle Cream
OGN
Organon and Co
Phase 3Active, not recruiting
was suspended
187Aug 2027Registry ↗
Nov 5, 2026Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
NCT05172726 · Plaque Psoriasis
tapinarof cream, 1%
OGN
Organon and Co
Phase 3Completed
was active, not recruiting
58Oct 14, 2026Registry ↗
May 8, 2026A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in…
NCT05560646 · Endometriosis
OG-6219, Placebo
OGN
Organon and Co
Phase 2Completed354May 28, 2025Registry ↗
Apr 8, 2026An Explorative Trial to Explore the Safety, Acceptability and Vaginal Bleeding Pattern of Three Eto…
NCT00967746 · Contraception
Etonogestrel-releasing IUS, Etonogestrel-releasing IUS
OGN
Organon and Co
Phase 2Completed84Nov 2010Registry ↗
Apr 8, 2026A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With…
NCT00651807 · Benign Prostatic Hyperplasia (BPH)
etonogestrel, Placebo
OGN
Organon and Co
Phase 2Terminated16Aug 2008Registry ↗
Feb 18, 2026A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of…
NCT04626596 · Contraception
Radiopaque Etonogestrel (ENG) Implant
OGN
Organon and Co
Phase 3Completed498Dec 30, 2024Registry ↗
Nov 21, 2025Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive
NCT05264506 · Contraception
NOMAC-E2 COC
OGN
Organon and Co
Phase 3Terminated3,055Jan 12, 2024Registry ↗
Sep 9, 2025Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Pat…
NCT05761444 · Atherosclerotic Cardiovascular Disease
Atozet 10/40 mg or 10/80 mg, Lipitor 40 mg or 80 mg
OGN
Organon and Co
Phase 4Completed137Sep 4, 2024Registry ↗
Sep 5, 2025Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
NCT05186805 · Atopic Dermatitis
Tapinarof cream, 1%
OGN
Organon and Co
Phase 2Completed36Aug 24, 2022Registry ↗
Sep 4, 2025Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults
NCT05014568 · Atopic Dermatitis
tapinarof cream, 1%, Vehicle cream
OGN
Organon and Co
Phase 3Completed407Mar 30, 2023Registry ↗
Sep 2, 2025Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)
NCT05032859 · Atopic Dermatitis
tapinarof cream, 1%, vehicle cream
OGN
Organon and Co
Phase 3Completed406Feb 3, 2023Registry ↗
Aug 13, 2025Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis
NCT05142774 · Atopic Dermatitis
Tapinarof cream, 1%
OGN
Organon and Co
Phase 3Completed728Feb 29, 2024Registry ↗
Aug 6, 2025Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
NCT04053387 · Plaque Psoriasis
tapinarof cream, 1%
OGN
Organon and Co
Phase 3Completed763Apr 6, 2021Registry ↗
Jun 19, 2025Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
NCT04042103 · Plaque Psoriasis
Tapinarof cream, 1%
OGN
Organon and Co
Phase 2Completed21Jan 9, 2020Registry ↗
Jun 12, 2025A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in t…
NCT05789576 · Psoriasis
VTAMA (tapinarof) cream, 1%
OGN
Organon and Co
Phase 4Completed31Jun 30, 2023Registry ↗
Jun 12, 2025A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque…
NCT05680740 · Psoriasis
VTAMA® (tapinarof) Cream 1%
OGN
Organon and Co
Phase 4Completed34May 18, 2023Registry ↗
Jun 12, 2025Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)
NCT03983980 · Plaque Psoriasis
Tapinarof, Vehicle Cream
OGN
Organon and Co
Phase 3Completed515May 13, 2020Registry ↗
Jun 12, 2025Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)
NCT03956355 · Plaque Psoriasis
Tapinarof, Vehicle Cream
OGN
Organon and Co
Phase 3Completed510May 26, 2020Registry ↗
Jun 4, 2025A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis
NCT02094235 · Atopic Dermatitis
E6005 0.05%, Placebo
OGN
Organon and Co
Phase 1/2Completed62Dec 2014Registry ↗
Jun 4, 2025A Study of E6005 in Japanese Patients With Atopic Dermatitis
NCT01179880 · Atopic Dermatitis
E6005, Placebo
OGN
Organon and Co
Phase 1/2Completed40Dec 2012Registry ↗
Jun 3, 2025A Phase 2 Study of E6005 in Patients With Atopic Dermatitis
NCT01461941 · Atopic Dermatitis
E6005, E6005 ointment (vehicle)
OGN
Organon and Co
Phase 2Completed78Nov 2012Registry ↗
Sep 19, 2024Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05787 (P0571…
NCT00703014 · Pregnancy, Neonates
Corifollitropin Alfa 150 μg, 200 IU RecFSH/Follitropin beta…
OGN
Organon and Co
—Completed541Apr 18, 2008Registry ↗
Sep 5, 2024A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)
NCT01414192 · Dyslipidemia, Hypercholesterolemia
OGN
Organon and Co
—Completed3,215Sep 15, 2014Registry ↗
Sep 5, 2024Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)
NCT00702520 · Pregnancy, Neonates
Corifollitropin alpha (MK-8962, Org 36286) 100 ug, Corifoll…
OGN
Organon and Co
—Completed15Nov 7, 2007Registry ↗
Sep 5, 2024Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P0571…
NCT00702338 · Pregnancy, Neonates
corifollitropin alfa, recombinant Follicle Stimulating Horm…
OGN
Organon and Co
—Completed1Aug 9, 2008Registry ↗
Sep 5, 2024Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in…
NCT00702273 · In Vitro Fertilization
150 µg Corifollitropin Alfa, 200 IU RecFSH/Follitropin beta…
OGN
Organon and Co
—Completed344May 19, 2009Registry ↗
Sep 5, 2024Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care…
NCT00702234 · Pregnancy, Neonates
Corifollitropin alfa, GnRH antagonist
OGN
Organon and Co
—Completed268Oct 22, 2009Registry ↗
Sep 5, 2024Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant…
NCT00070707 · Rhinitis, Allergic, Seasonal, Asthma
Mometasone, Placebo
OGN
Organon and Co
Phase 4Completed188Nov 26, 2003Registry ↗
Sep 4, 2024A Study to Evaluate the Safety of Combination Montelukast/Loratadine in Mexican Participants With A…
NCT01673620 · Allergic Rhinitis
Montelukast 10 mg/loratadine 10 mg, Placebo
OGN
Organon and Co
Phase 3Completed69Oct 10, 2012Registry ↗
Aug 29, 2024Survey of Osteoarthritis Real World Therapies (MK-0663-140)
NCT01294696 · Osteoarthritis
Standard of care for treatment of osteoarthritis (OA) of kn…
OGN
Organon and Co
—Completed1,261Jan 2013Registry ↗
Aug 23, 2024A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038)
NCT00092651 · Hypercholesterolemia
MK0653A, ezetimibe (+) simvastatin, Comparators: simvastati…
OGN
Organon and Co
Phase 3Completed1,398Jun 2003Registry ↗
Aug 15, 2024Japanese Bridging Trial of Org 37462 (Study P05969)(COMPLETED)
NCT00988260 · Controlled Ovarian Stimulation
Ganirelix, Ganirelix
OGN
Organon and Co
Phase 2Completed266Apr 12, 2004Registry ↗
Aug 15, 2024An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patien…
NCT00878462 · Psychosis
Asenapine WHITE raspberry flavor (Treatment A), Asenapine R…
OGN
Organon and Co
Phase 2Completed174Oct 15, 2005Registry ↗
Aug 15, 2024Comparison of the Effects of Desloratadine and Placebo in the Relief of Nasal Symptom Scores in Sub…
NCT00867191 · Seasonal Allergic Rhinitis
Placebo, Desloratadine
OGN
Organon and Co
Phase 4Completed233Apr 1, 2003Registry ↗
Aug 15, 2024A Randomized Trial Assessing Once Daily Administration of Mometasone Furoate DPI in Asthmatics (Stu…
NCT00835094 · Asthma
Mometasone furoate, Mometasone furoate
OGN
Organon and Co
Phase 4Completed216Jul 1, 2003Registry ↗
Aug 15, 2024Assessment of Intranasal Steroids in Allergic Rhinitis When Used Alone or in Combination With an Or…
NCT00834119 · Rhinitis, Allergic
Mometasone furoate, Mometasone furoate
OGN
Organon and Co
Phase 4Completed72Apr 1, 2004Registry ↗
Aug 15, 2024A Study to Determine the Efficacy and Safety of Two Mometasone Dry Powder Inhalers in the Treatment…
NCT00817817 · Asthma
MF, MF
OGN
Organon and Co
Phase 3Completed93May 1, 2003Registry ↗
Aug 15, 2024Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented…
NCT00817050 · Allergic Rhinitis
Mometasone Furoate Nasal Spray, fluticasone nasal spray
OGN
Organon and Co
Phase 4Completed100Jan 1, 2005Registry ↗
Aug 15, 2024The Effect of Desloratadine and Levocetirizine on Nasal Obstruction (Study P03609)
NCT00789152 · Allergic Rhinitis
desloratadine, levocetirizine
OGN
Organon and Co
Phase 3Completed81May 1, 2004Registry ↗
Aug 15, 2024Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented…
NCT00783458 · Allergic Rhinitis
Mometasone Furoate Nasal Spray, fluticasone nasal spray
OGN
Organon and Co
Phase 4Completed100Jan 1, 2005Registry ↗
Aug 15, 2024A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Stu…
NCT00783354 · Urticaria, Chronic Idiopathic Urticaria
desloratadine, desloratadine
OGN
Organon and Co
Phase 4Completed129Feb 1, 2004Registry ↗
Aug 15, 2024Onset of Effect of Mometasone Nasal Spray in Induced Allergic Rhinitis (Study P03431)
NCT00783237 · Allergic Rhinitis
Mometasone, Placebo
OGN
Organon and Co
Phase 4Completed340Feb 21, 2004Registry ↗
Aug 15, 2024Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal All…
NCT00783211 · Seasonal Allergic Rhinitis
desloratadine, fexofenadine
OGN
Organon and Co
Phase 4Completed722Oct 1, 2004Registry ↗
Aug 15, 2024Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal All…
NCT00783146 · Seasonal Allergic Rhinitis
desloratadine, fexofenadine
OGN
Organon and Co
Phase 4Completed728Oct 1, 2004Registry ↗
Aug 15, 2024Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P031…
NCT00783133 · Seasonal Allergic Rhinitis
Desloratadine 5 mg, fexofenadine
OGN
Organon and Co
Phase 4Completed131Jun 1, 2003Registry ↗
Aug 15, 2024Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray (Study P04419)
NCT00779740 · Rhinitis, Allergic, Perennial
mometasone furoate, mometasone furoate
OGN
Organon and Co
Phase 3Completed102Apr 1, 2005Registry ↗
Aug 15, 2024Effectiveness and Safety of Desloratadine in Patients With Allergic Airway Disease During the Polle…
NCT00779636 · Allergic Airway Disease
Desloratadine, Placebo
OGN
Organon and Co
Phase 4Completed506Nov 1, 2004Registry ↗
Aug 15, 2024A Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study P03748)(COMPLETED)
NCT00779545 · Rhinitis, Allergic, Perennial
Placebo, Mometasone furoate
OGN
Organon and Co
Phase 2Completed455Aug 6, 2004Registry ↗
Aug 15, 2024MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED)
NCT00771160 · Rhinitis, Allergic
montelukast sodium
OGN
Organon and Co
Phase 3Completed120Feb 2005Registry ↗
Aug 15, 2024Elocon vs Fluticasone in Localized Psoriasis (P03197)
NCT00763529 · Psoriasis
Mometasone, Fluticasone
OGN
Organon and Co
Phase 4Completed245Jan 1, 2005Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:34 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances